Oxaliplatin doublets in non-small cell lung cancer: A literature review

Diego Cortinovis, Paolo Bidoli, Nicoletta Zilembo, Alberto Fusi, Emilio Bajetta

Research output: Contribution to journalArticlepeer-review


Nowadays cisplatin doublets are considered the gold-standard treatment in advanced non-small cell lung cancer (NSCLC) patients, but are often associated to poor toxicity profile. In the last years different schedules have been developed in order to improve the tolerability of these regimens. Carboplatin is gradually replacing cisplatin in clinical practice as well as in clinical trials even if it is still unclear whether it has an equivalent efficacy compared to cisplatin. Oxaliplatin, the trans-l oxalato platinum compound, showed encouraging antineoplastic activity and favourable toxicity profile in NSCLC, but confirmatory randomized phase III trials are warranted. We performed a literature search in order to better understand the possible role of oxaliplatin-based combinations in advanced NSCLC treatment strategies.

Original languageEnglish
Pages (from-to)325-331
Number of pages7
JournalLung Cancer
Issue number3
Publication statusPublished - Jun 2008


  • Chemotherapy
  • Doublet chemotherapy regimens
  • Non-small cell lung cancer
  • Oxaliplatin
  • Platinum analogue
  • Review

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Oxaliplatin doublets in non-small cell lung cancer: A literature review'. Together they form a unique fingerprint.

Cite this